Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
Clinical Infectious Diseases · 09.02.2026 · 82 (1) · e176-e184
DOI: 10.1093/cid/ciaf281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 31.05.2025. Verfasst von Jennifer Audsley und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, HIV Infections, Hepatitis B, Chronic, Coinfection. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHMRC, APP.
Abstract (Originalsprache)
Background
An effective therapeutic strategy for hepatis B virus (HBV) cure remains an urgent unmet need. We aimed to define the incidence, kinetics, and predictors of hepatitis B surface antigen (HBsAg) loss in people with HIV and HBV (PWH-HBV) following HBV-active antiretroviral therapy (ART) in PWH-HBV in Asia.
Methods
97 PWH-HBV commencing HBV-active ART were recruited prospectively in Thailand (n = 94) and Malaysia (n = 3), then followed for 24 months. Time to HBV serology change was calculated. Univariate associations between baseline characteristics and HBsAg loss were examined using the Mann-Whitney or chi-square tests. Multivariable analysis was undertaken using Cox regression.
Results
Twenty-one individuals (22%) lost HBsAg during follow-up (11.7 per 100 person-years), 14 of whom gained anti-HBs. Twenty-two of 61 (36.1%) individuals who were hepatitis B “e” antigen (HBeAg) positive at baseline lost HBeAg over the study, 15 of whom gained anti-HBe. Most individuals lost HBsAg and HBeAg by the month 12 study visit (81% and 63.6%, respectively), with median times of 5.8 and 12.0 months to HBsAg and HBeAg loss, respectively. Univariate analysis showed baseline characteristics associated with HBsAg loss were higher alanine aminotransferase (ALT; P = .005), tenofovir alafenamide (TAF)–containing ART regimen (P = .025), younger age (P = .040), lower liver stiffness (P = .010), and quantitative HBsAg < log10 2.0 IU/mL (P = .001). All 5 factors remained significant in a Cox regression analysis that adjusted for baseline CD4 count.
Conclusions
High HBsAg loss rates occur in PWH and HBV early after commencing ART. Our study suggests that TAF-containing ART regimens may be preferable as first-line therapy in HIV-HBV coinfection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
- HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS and Infectious Diseases Research Centre (AIDSID), and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn Uni…
- Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
- Infectious Diseases Medical Centre, Voluntary Health Services Hospital, Chennai, India.
- Public Health, Burnet Institute, Melbourne, Australia.
- Department of Medicine, University of Adelaide, Adelaide, Australia.
ORCID-Profile: Jennifer Audsley, Anchalee Avihingsanon, Rosalind Edwards, Hay Mar Su Lwin, Sivaporn Gatechompol
Förderung
- NHMRC
- APP
Zitieren
APA
Audsley, J., Avihingsanon, A., Li, X., Edwards, R., Jackson, K., Warner, N., Maslac, O., Revill, P. A., Lwin, H. M. S., Gatechompol, S., Kumarasamy, N., Spelman, T., Azwa, I., Kamarulzaman, A., Lewin, S. R., & Sasadeusz, J. (2026). Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection. Clinical Infectious Diseases, 82(1), e176-e184. https://doi.org/10.1093/cid/ciaf281
Vancouver
Audsley J, Avihingsanon A, Li X, Edwards R, Jackson K, Warner N, et al. Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection. Clinical Infectious Diseases. 2026;82(1):e176-e184. doi:10.1093/cid/ciaf281
BibTeX
@article{Audsley2026,
author = {Audsley, Jennifer and Avihingsanon, Anchalee and Li, Xin and Edwards, Rosalind and Jackson, Kathy and Warner, Nadia and Maslac, Olivia and Revill, Peter A and Lwin, Hay Mar Su and Gatechompol, Sivaporn and Kumarasamy, Nagalingeswaran and Spelman, Tim and Azwa, Iskandar and Kamarulzaman, Adeeba and Lewin, Sharon R and Sasadeusz, Joe},
title = {Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {1},
pages = {e176--e184},
doi = {10.1093/cid/ciaf281}
}
EUVIMED